$0.72
3.38% yesterday
Nasdaq, Nov 25, 08:31 pm CET
ISIN
KYG6096M1069
Symbol
APM
Sector
Industry

Aptorum Group Limited Class A Stock price

$0.70
-0.95 57.58% 1M
-3.89 84.75% 6M
-1.75 71.41% YTD
-0.93 57.06% 1Y
-18.00 96.26% 3Y
-152.70 99.54% 5Y
-142.80 99.51% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.04 5.41%
ISIN
KYG6096M1069
Symbol
APM
Sector
Industry

Key metrics

Market capitalization $3.63m
Enterprise Value $-4.48m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.58
EV/Sales (TTM) EV/Sales -10.42
P/S ratio (TTM) P/S ratio 8.44
P/B ratio (TTM) P/B ratio 0.15
Revenue growth (TTM) Revenue growth -66.71%
Revenue (TTM) Revenue $430.00k
EBIT (operating result TTM) EBIT $-10.53m
Free Cash Flow (TTM) Free Cash Flow $-7.78m
EPS (TTM) EPS $-0.91
Short interest 0.17%
Show more

Is Aptorum Group Limited Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Aptorum Group Limited Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Aptorum Group Limited Class A:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Aptorum Group Limited Class A:

Buy
100%

Financial data from Aptorum Group Limited Class A

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '23
+/-
%
0.43 0.43
67% 67%
100%
- Direct Costs 1.55 1.55
36% 36%
360%
-1.12 -1.12
1% 1%
-260%
- Selling and Administrative Expenses 4.16 4.16
41% 41%
967%
- Research and Development Expense 4.13 4.13
49% 49%
960%
-9.40 -9.40
42% 42%
-2,186%
- Depreciation and Amortization 1.13 1.13
7% 7%
263%
EBIT (Operating Income) EBIT -11 -11
40% 40%
-2,449%
Net Profit -2.82 -2.82
71% 71%
-656%

In millions USD.

Don't miss a Thing! We will send you all news about Aptorum Group Limited Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Aptorum Group Ltd. is a pharmaceutical company, which engages in the development and commercialization of therapeutic and diagnostic technologies. It operates through the Therapeutics and Non-Therapeutics segments. The Therapeutics segment seeks to develop various drug molecules and certain technologies for the treatment and diagnosis of human disease conditions in neurology, infectious diseases, gastroenterology, oncology, and other disease areas. The Non-Therapeutics segment encompasses the development of surgical robotics and medical devices; and the activities of AML Clinic. The company was founded by Ian Huen on September 13, 2010 and is headquartered in Hong Kong.

Head office Cayman Islands
CEO Ian Huen
Employees 3
Founded 2010
Website www.aptorumgroup.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today